NEW YORK, Aug. 12, 2025 /PRNewswire/ — HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined the prestigious Mayo Clinic Platform Accelerate program. This partnership grants HopeAI access to Mayo Clinic’s world-class real-world data (RWD) platform, enabling faster, smarter, and more confident clinical trial design.
Bringing a new drug to market is one of the most complex and costly challenges in modern healthcare. Globally, pharmaceutical companies spend over $300 billion each year on R&D, with an average 12-year timeline from discovery to market. 70% of the time and cost is consumed by clinical trials — yet a staggering 90% of drug candidates ultimately fail before reaching patients.
- A Problem That Affects Us All Every failed late-stage trial can delay important treatments for cancer, heart disease, or rare conditions — sometimes by years — and drive up future healthcare costs.
- How HopeAI Can Help By combining trusted real-world medical data with powerful AI and statistical models, HopeAI can help researchers design trials faster, select the right patients more accurately, and make results more reliable. This means promising treatments could reach patients sooner and with a higher chance of success.
- A Rare and Valuable Partnership Being chosen for Mayo Clinic’s Accelerate program is a strong signal of quality and credibility. HopeAI now stands alongside a small, select group of innovators who can work directly with Mayo’s experts and unique data resources to bring smarter healthcare solutions to the world.
One standout development is HopeAI’s AI Agents, built in collaboration with HemOnc.org, the world’s largest medical wiki for cancer treatment. This tool supports clinicians and trial designers by rapidly generating evidence-based recommendations, identifying optimal patient groups, and reducing costly trial delays.
HopeAI has already signed two of the world’s top ten pharmaceutical companies as customers, alongside several cutting-edge biotech innovators. This early adoption demonstrates strong market demand and commercial scalability — critical factors for future revenue growth and investor confidence.
The partnership with Mayo Clinic Platform marks a pivotal milestone for HopeAI, positioning the company at the intersection of AI, big data, and precision medicine. With an addressable market worth hundreds of billions annually, and the ability to directly impact both R&D efficiency and patient outcomes, HopeAI is dedicated to bringing hope to patients through AI-accelerated clinical development.
Media Contact: PR Team: Xiaomai Zhang, xiaomai@hopeai.co
About HopeAI
HopeAI is to bring hope to patients by accelerating the clinical development of new treatments through the power of AI. By integrating comprehensive clinical evidence with cutting-edge statistical innovation, HopeAI facilitates optimized clinical trial design, improves patient recruitment, enhances real-world, evidence-based decision-making, synthesizes data-driven support, and increases the probability of success in clinical development. For more information about HopeAI and its AI-driven solutions, visit https://hopeai.co/
View original content to download multimedia:https://www.prnewswire.com/news-releases/hopeai-joins-mayo-clinic-platform-to-transform-the-future-of-drug-development-with-ai-302528569.html
SOURCE HopeAI, Inc.
